Quilaban invests in high-resolution technologies through new partnership with Waters

The new strategic partnership with Waters reinforces Quilaban’s commitment to advanced analytical solutions for clinical diagnostics in Portugal.

Quilaban has announced a new strategic partnership with Waters, a world-leading company in liquid chromatography and mass spectrometry technologies, strengthening its portfolio in the Clinical Diagnostics area.

This collaboration marks the beginning of a project focused on expanding liquid chromatography applied to clinical laboratories, with the aim of providing more precise, efficient analytical solutions tailored to the current requirements of Portuguese laboratories.

As part of this partnership, the Quilaban team has benefited from specialised technical training, enabling them to deepen their knowledge of the practical applications of these technologies in a clinical context. This investment ensures qualified and specialised support for customers.

“The future of laboratory diagnostics relies on high-resolution technologies that enable more precise, evidence-based clinical decisions. The partnership between Quilaban and Waters strengthens Portuguese laboratories’ access to advanced chromatography and mass spectrometry solutions, with cross-cutting application in clinical diagnostics, from the identification of biomarkers and metabolites to therapeutic drug monitoring”, states Cláudia Duarte, Product & Applications Manager at Quilaban.

The initiative is part of Quilaban’s strategy to promote technological innovation and support Portuguese laboratories in optimising their processes and responding to future clinical diagnostics challenges.